VolitionRx's Nu.Q® Cancer Test Shows Prognostic Value in Lung Cancer Study
Event summary
- VolitionRx's Nu.Q® Cancer Assay demonstrated significant prognostic value in a clinical study involving newly diagnosed lung cancer patients.
- The study, conducted with Hospices Civils de Lyon, showed that the test can predict survival outcomes and enhance treatment selection.
- VolitionRx aims to submit a reimbursement dossier under France's RIHN framework, with eligibility determination expected within five months of admissibility.
- The company anticipates €50 per test as revenue in its direct sales model and is exploring licensing opportunities internationally.
The big picture
VolitionRx's study results position its Nu.Q® Cancer Assay as a tool for personalized treatment selection in lung cancer, aligning with broader trends toward precision medicine. The company's focus on securing reimbursement and expanding commercially reflects the strategic importance of regulatory milestones in the biotech sector.
What we're watching
- Regulatory Approval
- The pace at which VolitionRx secures reimbursement approval in France will determine the test's market entry timeline.
- Commercial Expansion
- Whether VolitionRx can successfully license its technology to third-party collaborators beyond France.
- Clinical Adoption
- How quickly the Nu.Q® Cancer test is integrated into routine clinical practice following approval.
Related topics